

Supporting Information:

A two-step immunocapture LC-MS-MS assay for plasma stability and payload migration assessment of cysteine-maleimide based antibody drug conjugates

Linlin Dong,^{†*} Chao Li,^{†‡} Charles Locuson,[†] Susan Chen,[†] Mark Qian[†]

[†]Department of Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International, Inc., 35 Landsdowne Street, Cambridge, MA 02139

[‡]Present address: Nuventra Pharma Sciences, 2525 Meridian Parkway, Durham, NC 27713

Contents:

Supplemental Methods

Figure S-1 **Recovered payload concentration in each fraction of plasma stability samples**

Supplemental Methods

Quantitation of Conjugated Payload and Total Antibody Using Single Step

Immunocapture. For conjugated payload analysis, an aliquot of 10 μL each stability sample was dispensed into a 96-well Thermo Kingfisher plate with 150 μL of PBS (pH 7.4) and 0.1 mg (100 μL) target antigen coupled M-280 beads pre-added. Samples were mixed well on a shaker and allowed 40 min for ADCs to bind at room temperature. The plate was then processed with a KingFisher™ Flex magnetic particle processor as described by Xu et al.¹ Then the beads were released into 100 μL of papain activation solution. Twenty μL of 10 mg/mL activated papain solution (preactivated at 37°C for 15 min) were added to each sample well. Microwave assisted digestion was performed in the REDS at 37°C for 45 minutes. Then the sample was immediately acidified by adding 10 μL of 20% TFA. An aliquot (160 μL) of 6.25 ng/mL d8-MMAE was spiked to the sample as the internal standard (prepared in 95% acetonitrile and 0.1% formic acid in water). The plate was then vortexed for 1 min and centrifuged at 2100xg for 10 min. One μL of supernatant was injected to the LC-MS.

For total antibody analysis, the same immunocapture procedure was carried out. However, the TAK-maleimide-TPP ADC was eluted from the magnetic beads using 100 μL of 25% acetonitrile/30 mM HCl instead.² Following the elution, 20 μL of 1 M Tris (pH 8) was added to the eluent. Then 10 μL of 1% RapiGest and 10 μL of Lys-C (0.33 $\mu\text{g}/\mu\text{L}$ in water) were added to each sample well. Preincubation of 30 min at 37°C was followed by 20 min microwave assisted digestion under conditions described above. The sample was then immediately acidified by

adding 10 μ L of 20% TFA. Twenty μ L of 1 μ g/mL SIL-HC peptide (prepared in 20% acetonitrile) was spiked to the sample as the internal standard followed by adding 80 μ L of 50% acetonitrile then centrifuge for 10 minutes at 2100xg. Ten μ L of supernatant was injected to the LC-MS.

Both conjugated payload and total antibody were quantified against an ADC standard based calibration curve.


Quantitation of Deconjugated Payload and Free Payload (TPP). An aliquot of 30 μ L each stability sample was first added to a 96-well extraction plate. Then 15 μ L of d8-MMAE (10 ng/mL in 20% acetonitrile) was spiked to the sample as the internal standard followed by adding 160 μ L acetonitrile. The plate was centrifuged for 10 minutes at 2100xg. Five μ L of supernatant was injected to the LC-MS.

Liquid Chromatography and Mass Spectrometry. A Shimadzu Nexera UHPLC system (Kyoto, Japan) was interfaced to an AB Sciex 5500 QTRAP mass spectrometer (Framingham, MA). The reversed phase UHPLC separation was carried out on a Waters BEH C4 300 Å column (50x2.1 mm, 3.5 μ m) with two separate gradients depending on analytes of interest. Mobile phase A (water containing 0.1% FA) and mobile phase B (acetonitrile containing 0.1% FA) were used for both gradient elutions at 0.6mL/min and at 50 °C. For the surrogate peptide analysis, the gradient employed was as follows: 0 min, 5 % B; 0.4 min, 5 % B; 1.7 min, 90% B; 2.5 min, 90% B; and 2.51-3 min, 5% B. For TPP analysis, the gradient used was as follows: 0 min, 10 % B; 1.3 min, 50 % B; 1.5 min, 90% B; 2.3 min, 90% B; and 2.31-3 min, 10% B. LC-

MS-MS data were collected and processed using Analyst software 1.6.2 (Build 8489) provided by AB Sciex.

Figure S-1. Recovered payload concentration in each fraction of plasma stability samples

(n=2) (a) mouse (b) human



Supplemental References:

- (1) Xu, L.; Packer, L. E.; Qian, M. G.; Wu, J.-T. *Journal of Pharmaceutical and Biomedical Analysis* **2016**, 128, 226-235.
- (2) Xu, L.; Packer, L. E.; Li, C.; Abdul-Hadi, K.; Veiby, P. *Analytical Biochemistry* **2017**, 537, 33-36.